As 2012 Begins, NASDAQ Reports That New HCV Drugs Are At The Forefront Of Another Year Of Sky High Pharmaceutical Profits

A Booming Biotech High With HCV Market Overflowing:

There is a Question of Love, a Question of Our Humanity —

Can People Come Before Profits?

A Common Goal With The Occupy Movement - People Before Profits

Another Year, Another High… The biotechnology sector, though a risky investment arena, offers a tremendous potential for huge gains. Binary events like clinical trial results and FDA decisions are typical in biotechnology companies, and can cause significant swings in share price. The following are some of our bio stock picks of 2011 that have been setting new highs.

Pharmaceuticals Inc. (IDIX) is a biopharmaceutical company building a pipeline of drug candidates for hepatitis C, a market with high levels of unmet need. IDIX was trading around $5.06 when we alerted readers to the stock on September 6, 2011, and it set a new 52 week high of $15.25 in intraday trading on Jan.19, 2012, representing a gain of 201 percent. The stock closed Friday's trading at $11.68.

The acquisition of Inhibitex Inc. (INHX), a hepatitis C drug developer, by Bristol-Myers Squibb Company Co (BMY) on Jan.9, for $26 a share, or about $2.5 billion, which was a 163% premium, sparked an interest in other hepatitis C drugmakers.

Achillion Pharmaceuticals Inc. (ACHN) is a biopharmaceutical company focused on the development of antivirals for the treatment of chronic hepatitis C. ACHN was trading around $4.37 when we alerted readers to the stock on October 7, 2011, and it set a new 52 week high of $12.95 in intraday trading on Jan.13, 2012, which implies a gain of 196 percent. The acquisition of Inhibitex Inc. (INHX), a hepatitis C drug developer, by Bristol-Myers Squibb Company Co (BMY) on Jan.9, for $26 a share, or about $2.5 billion, which was a 163% premium, sparked an interest in other hepatitis C drugmakers.

Based upon recent results of clinical trials, Achillion is planning further exploration of ACH-1625 in combination with other oral antiviral agents for the treatment of all HCV genotypes and continues to evaluate ACH-2684 in a phase 1 clinical trial. Achillion plans to submit an investigational new drug application and initiate a phase 1 clinical trial with ACH-3102 during the second quarter of 2012. During the second half of 2012, Achillion plans to initiate an interferon-free, all-oral combination clinical study evaluating a protease inhibitor and a NS5A inhibitor, with or without ribavirin, for the treatment of HCV.

Can Profits Before People Shift To People Before Profits In Health Industry

Without question, the development of an interferon free, all oral protease inhibitor will revolutionize worldwide the HCV market. The question is can the people come before the profits. If the treatments costs too much and is too expensive for people to access without bucket loads of assets or the perfect insurance plan, then this is not what the world needs. The focus has to be that everyone should be taken care of and given access to a treatment that potentially can and will save lives.

The Shift Must Be Made - 

People Before Profits, Not Profits Before People 

When It Comes Down To The Health Industry

The So-Called Biotechnology Sector
?Beyond Our Understanding?
No More Excuses or Rationalizations

Accessible Medical Treatment For All!